Challenges in the treatment of cystic fibrosis in the era of CFTR modulatorsAuthors' replyUse of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele a systematic review and meta-analysisDiscontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY) results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsAssessing Safety of Discontinuing Hypertonic Saline in Those with Lower Forced Expiratory Volume in 1 Second after Elexacaftor/Tezacaftor/Ivacaftor.
J Bras Pneumol
; 50(2): e20240107, 2024 May 27.
Article
em En
| MEDLINE
| ID: mdl-38808835
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Quinolonas
/
Regulador de Condutância Transmembrana em Fibrose Cística
/
Fibrose Cística
/
Benzodioxóis
/
Aminofenóis
/
Indóis
Limite:
Humans
Idioma:
En
Revista:
J Bras Pneumol
Ano de publicação:
2024
Tipo de documento:
Article
País de publicação:
BR
/
BRASIL
/
BRASILE
/
BRAZIL
/
BRESIL